Did you know?
From October 2015, the 18-month schedule point on the National Immunisation Program (NIP) will include the reinstated dose of diphtheria-tetanusacellular pertussis (DTPa) vaccine to reduce pertussis notifications in young children and reduce transmission to infants too young to be immunised.
The Pertussis Chapter (Chapter 4.12) of The Australian immunisation handbook (10th Edition) has been updated to include the addition of the booster dose at 18 months of age. It also adds the preference for pertussis vaccination (the reduced content dTpa formulation) in every pregnancy (third trimester) to improve protection against pertussis in young infants. Chapter 4.12 also provides updated information and evidence. The updated chapter is only available in HTML at <www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/ Handbook10-home>.
From November 2016, a National Shingles Vaccination Program will be rolled out as an ongoing program for 70 year olds, with a five-year catch-up program for 71-79 year olds. This program will reduce cases of herpes zoster and its complications in the older population.
Between April and June 2015, four doses of bioCSL's Fluvax ® vaccine were administered to children under five years of age in Victoria. In addition, 32 bioCSL Fluvax ® doses were misreported to the Australian Childhood Immunisation Register. Continue to educate all new doctors and nurses not to administer bioCSL Fluvax ® influenza vaccine to children aged six months to under five years of age. Alternative brands are available and can be safely used for this age group. Continue to educate all new doctors and nurses about the advice to not administer bioCSL Fluvax ® influenza vaccine to children six months to under five years of age. Take care to accurately report vaccines administered to children younger than seven years of age to the ACIR.
• Providers are reminded that bioCSL Fluvax ® is not registered for use in children under five years of age in Australia and should not be given in this age group due to an increased risk of febrile convulsions.
• The Australian Technical Advisory Group on Immunisation recommends the use of Fluarix ® and Vaxigrip ® for children between six months and 10 years of age eligible for influenza vaccination under the NIP.
• All influenza vaccines may be used in anyone aged 10 years or over.
There may be a small increase in the risk of fever and febrile convulsions with the co-administration of trivalent influenza and pneumococcal conjugate vaccines in children 12-23 months of age. These vaccines may still be given together but providers should discuss this small risk with parents prior to vaccination. If vaccines are given separately, ensure an interval of at least three days between each vaccine.
Seasonal influenza vaccine is recommended and free for all people who are at high risk of a poor outcome after influenza infection. Send reminders to your eligible patients or remind them when they attend your service.
The following groups are eligible for free, governmentsupplied seasonal influenza vaccine:
• people aged 65 years and older
• pregnant women, at any time during their pregnancy
• Aboriginal and Torres Strait Islander people aged six months to under five years and 15 years and older
• residents of nursing homes and other long-term care facilities
• any person over six months of age with a condition predisposing them to severe influenza illness requiring regular medical follow-up or hospitalisation, including children aged six months to 10 years undergoing longterm aspirin therapy Who is eligible to receive the free vaccine?
The following people living in Victoria are eligible to receive the free vaccine from 1 June 2015:
• pregnant women from 28 weeks gestation during every pregnancy
• partners of women who are at least 28 weeks pregnant if the partner has not received a pertussis booster in the last 10 years
• parents/guardians of babies born on or after 1 June 2015, if their baby is under six months of age and they have not received a pertussis booster in the last 10 years.
These eligibility requirements are based on the best scientific evidence available, the opinion of immunisation experts, and the recommendations from The Australian immunisation handbook, 10th Edition, 2013 (updated April 2015 .
Are only mothers and fathers eligible for the vaccine?
No. As well as pregnant and postpartum women, any person who considers themself to be a parent or guardian of a newborn baby is eligible. This includes, but is not limited to, fathers, same-sex partners, foster parents, adoptive parents, surrogate parents, co-parents, and any other legal guardians.
Are grandparents eligible for the free vaccine?
Grandparents are only eligible for the free vaccine if they are the primary carer or legal guardian of the newborn baby. All other grandparents in close contact with newborns can purchase vaccine with a private prescription.
Do eligible parents have to live in Victoria?
Yes. To be eligible for the free vaccine adults must ordinarily reside in Victoria, hold a Medicare card, or be a permanent resident or have applied for permanent residency. All other people who meet the recommended guidelines for pertussis vaccination can purchase vaccine with a private prescription.
Are parents of children born before 1 June 2015 eligible for free vaccine?
No. Only parents of children born on or after 1 June 2015 are eligible for free vaccine. All other parents and close contacts who meet the recommended guidelines for pertussis vaccination can purchase vaccine with a private prescription.
Resources for patients
A fact sheet for patients and a poster for display at health services are available free by ordering online at <ideas. Protect your baby by protecting yourself with a free whooping cough vaccine I've heard that vaccina ted people can still catch whoopi ng cough. Is this true?
The adult vaccine is around ninety-tw o per cent effective; meaning that some people who are vaccinate d may still catch whooping cough.
The whooping cough vaccine is the best protectio n available to prevent the spread of this disease.
What other vaccine s are recomm ended during pregna ncy?
Influenza (flu) vaccine is recomme nded at any time during pregnanc y and is free for pregnant women.
Influenza infection can cause serious complica tions in a pregnant woman, which may include the need for hospital treatmen t. Evidence shows that vaccinati on against influenza while pregnant can provide protectio n for the baby in the first six months after birth.
How safe are the recomm ended vaccine s during pregna ncy?
The recomme nded vaccines are safe during pregnanc y and while breastfee ding.
Whoopin g cough vaccine has been routinely given to pregnant women in the United Kingdom and the United States of America for several years and is recomme nded for all pregnant women in Australia. A number of largescale scientific studies from the UK and US have shown no increased risk of any adverse outcome s for mothers or babies.
Similarly, influenza vaccine has been provided free to pregnant women in Australia since 2010 and is recomme nded for every pregnanc y.
It is importan t to be comforta ble with decisions you make about vaccinati on during pregnanc y. Your doctor or immunisa tion provider is a good source of informatio n if you have questions or concerns about vaccine safety.
Where can I get further informa tion about whoopi ng cough, influenz a and the vaccine s during pregna ncy?
More informatio n is available from:
• your doctor or practice nurse
• your obstetric ian Except where otherwise indicated, the images in this publication show models and illustrative settings only, and do not necessarily depict actual services, facilities or recipients of services.
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Proposed changes to immunisation requirements
The Australian Government is proposing strengthening the immunisation requirements for child care and family benefits.
From 1 January 2016, subject to the passage of legislation, immunisation requirements already in place will apply to children of all ages for:
• Child Care Benefit (CCB)
• Child Care Rebate (CCR)
• Family Tax Benefit (FTB) Part A end of year supplement.
Source: Australian Government Department of Human Services at <www.humanservices.gov.au/customer/news/proposed-changes-toimmunisation-requirements
From 1 January 2016, families with children who are not immunised (and do not have an approved exemption) will not receive the FTB Part A end of year supplement and child care subsidies (subject to the passage of legislation). Vaccine objection will no longer be an exemption category. Families with children that do not have a medical exemption (medical contraindication or natural immunity certified by an immunisation provider) will not receive CCB, CCR, and the FTB Part A end of year supplement for that child (except for children under 12 months for the FTB Part A supplement).
Under the reforms, families need to have their children immunised in order to receive the FTB Part A supplement for that child. This means, for any year a child is not up to date with their immunisation, the end of year FTB Part A supplement will not be paid for that child. The supplement, which is worth up to $726 per child, is payable at the end of the financial year. Source: Department of Social Services at <www.dss.gov.au/our-responsibilities/familiesand-children/benefits-payments/strengtheningimmunisation-for-young-children>.
Improving immunisation coverage rates
The Australian Government will provide funding of $26.4 million over four years to increase national immunisation coverage rates. While childhood immunisation rates in Australia are high, with over 92 per cent of five year olds fully vaccinated, pockets of low coverage remain, putting those communities at risk.
Activities under this initiative will:
• provide an incentive to immunisation providers to complete 'catch-up' vaccinations
• include activities to improve the community's understanding and awareness of the National Immunisation Program
• broaden and improve immunisation data capture to assist immunisation providers boost coverage rates.
Incentive payments to immunisation providers
The Australian Government will provide incentives to immunisation providers to encourage them to follow up on children who are overdue for vaccinations. From 1 July 2016, immunisation providers, including doctors, will receive an incentive payment each time they identify a child in their practice who is overdue for vaccination and call them in for catch-up vaccines. This initiative will recognise immunisation providers' efforts to improve coverage rates, particularly in low coverage regions where there are more overdue children.
A payment will be made if a child was previously more than two months overdue for vaccination and has been subsequently caught-up. The payment is $6 for each childhood schedule point caught-up, a potential $36 if a child requires catch-up for the full childhood schedule. This is in addition to the notification payment immunisation providers currently receive.
Awareness campaign
The Australian Government is investing in an awareness campaign to promote community understanding of the importance of vaccinating and to support immunisation providers, such as GPs. The communications campaign will include a wide range of activities based on comprehensive market research and will focus on increasing awareness and understanding of the National Immunisation Program and addressing parents' concerns about immunisation, including dispelling common myths. Increased investment in tools for doctors and nurses will help them have often difficult discussions with parents and will allow parents to make an informed decision about immunisation.
New vaccines to be listed on the National Immunisation Program
The Australian Government, as part of the 2015-16 Federal Budget, has approved funding to list two vaccines on the National Immunisation Program (NIP):
• an additional dose of pertussis-containing vaccine for children
• a shingles vaccine for older Australians.
Victoria recently funded Boostrix ® vaccine for the parent's pertussis vaccine program, and the near future will bring new vaccines onto the National Immunisation Program schedule. Now is the time to consider if your vaccine fridge has the capacity to store the additional vaccine at 18 months of age, the parent pertussis vaccine, the annual seasonal influenza vaccine and the future shingles vaccine for the older population.
Air must circulate around the vaccines and the vaccines must not touch the back or side internal walls. Always keep vaccines in their box. Consider having two fridges rather than one large fridge to provide a backup in the event of a mechanical failure in one of the fridges. A purpose-built vaccine fridge is designed to maintain temperatures between 2 °C and 8 °C on all shelves.
Vaccines are delicate biological substances that can become less effective or be destroyed if they are frozen, overheated or exposed to direct sunlight or fluorescent light. A fridge with a solid door is preferred if the clinic is prone to power outages.
Points to consider 1. ICS Pacific brand will not guarantee vaccine storage conditions between 2 °C and 8 °C when the room temperature goes below 5 °C or above 30 °C or when the humidity is above 60 per cent. Are your heaters or air conditioners turned off after hours leading to temperature fluctuations? 2. Position the fridge out of direct sunlight, with space around it to promote air circulation. An internal room that does not have wide temperature fluctuations is best.
3. Fridges should preferably have a backup data logger, since it also shows the duration of a temperature breach.
4. After-sales service is important as vaccine fridges should be serviced annually. Consider the capacity of your vaccine fridge to store new vaccines Updated cold chain advice fridge magnet
All immunisation providers should follow the principles of safe vaccine storage management to ensure that clients receive effective and potent vaccines. Enclosed with this newsletter is an updated fridge magnet to guide your decision making for managing a vaccine excursion.
Order your free fridge magnets for your vaccine fridges from the immunisation resource page at <ideas. health.vic.gov.au/resources-immunisation.asp>.
From October 2015, the 18-month schedule point on the NIP will include the reinstatement of the dose of diphtheriatetanus-acellular pertussis (DTPa) vaccine. This additional dose will reduce pertussis notifications in young children and reduce transmission to infants too young to be immunised.
The start dates are subject to vaccine supply for these programs.
ProQuad ® -an additional MMRV vaccine brand
ProQuad ® is a new brand of measles, mumps, rubella and varicella (MMRV) vaccine that will be introduced onto the National Immunisation Program schedule from July 2015. This means you may receive either MMRV brand for use in children at 18 months of age.
The following table compares the two brands of MMRV vaccines that will be distributed for the 18 month-old schedule point on the National Immunisation Program. Make sure that your medical software program is updated in order to report the current vaccines to the Australian Childhood Immunisation Register (ACIR).
Menitorix
® -report to ACIR as dose one of meningococcal C This is the first dose of the meningococcal C component. ACIR will search for previously reported Hib doses for the child and automatically record the Hib component accordingly (routinely dose four).
Priorix-Tetra ® or ProQuad ® -report to ACIR as dose two of MMR This is the second dose of the MMR component. ACIR will search for a previously reported varicella vaccine dose for the child and automatically record the varicella vaccine dose accordingly (routinely dose one).
6 SAEFVIC -varicella case study*:
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An 18-month-old previously healthy child flew from the United Kingdom (UK) to Australia for a holiday. While on the plane, the child's mother noted a few lesions on his face. A few days after they arrived the child became febrile, had reduced oral intake and his eye became swollen and he was unable to open it. The patient presented to the Emergency Department and was admitted to a medical ward. A swab from skin lesions confirmed varicella and a swab from the eye showed heavy growth of Streptococcus Pyogenes (Group A Streptococcus). The child was also seen by the ophthalmologist who confirmed right eye periorbital cellulitis with right eye keratoconjunctivitis. The patient received intravenous antibiotics and Aciclovir and was commenced on Chlorsig. After three days he was discharged on oral Amoxicillin and Chlorsig drops and ointment. He had follow-up with an ophthalmologist. Final diagnosis was Group A Streptococcus periorbital cellulitis secondary to varicella infection.
All of the child's immunisations were up to date according to the UK schedule. Varicella is currently not on their vaccine schedule. The child's five-year-old brother also had varicella infection at the same time. *Note: consent was obtained from the family for this case report.
Varicella: Varicella (chickenpox) is a highly contagious infection caused by the varicella-zoster virus. Its main transmission is by respiratory secretions (air transport or coughing infected droplets). It can also be spread by direct contact with vesicle fluid of skin lesions.
Clinical symptoms for varicella include a rash that contains fluid-filled blisters that turn into scabs. Other symptoms that often occur prior to the rash include fever, lethargy, loss of appetite and headache.
Varicella is usually a mild disease, however in about one per cent of cases, complications do occur and can include secondary bacterial skin infection, pneumonia, acute cerebellar ataxia, aseptic meningitis, transverse myelitis, encephalitis and thrombocytopenia (The Australian immunisation handbook, 10th edition 2013). (Marshall, et al., 2013) . This decline in hospitalisation and mortality has also been noted in the United States where their varicella vaccination program has been in place since 1995 (The Australian immunisation handbook, 10th edition 2013). The case study highlights the importance of varicella vaccination as secondary complications such as skin infections and periorbital cellulitis does occur.
Recommendations: In Australia it is recommended that all children aged less than 14 years should have at least one dose of varicella-containing vaccine. A single dose is routinely administered at 18-months of age as a combined measles-mumps rubella-varicella vaccine. In Victoria a catch-up dose is administered to adolescents in Year 7 (aged 12 to 13 years) of secondary school. This case highlights the importance of catch-up vaccination for children emigrating from the UK. Adverse events following vaccines containing varicella are generally mild and well tolerated. The most common reported reactions are injection site reactions. A varicella vaccine associated rash can also occur about five to 26 days post vaccine (The Australian immunisation handbook, 10th edition 2013).
References and further reading:
Changes INSIG aims to provide a forum that facilitates communication, discussion and encourages professional development for immunisation nurses in the State of Victoria.
Since 2014, INSIG has expanded membership to include Associate members-this opens up membership to those working in the area of immunisation but who are not in a direct clinical role. This opportunity enables all team members of an immunisation service to network and share ideas.
By becoming a member, you will be tapping into an invaluable resource that is designed and expected to grow in the future.
INSIG Objectives:
• To promote recognition of immunisation nurses as a professional nursing specialty and raise public awareness of the profession
• To facilitate professional development within the Special Interest Group and immunisation industry by organising guest speakers, seminars and workshops
• To provide peer support and an environment in which immunisation nurses can network, exchange knowledge and seek information
• To investigate issues of concern and make recommendations
• To promote special research and special projects in the area of immunisation Invasive Pneumococcal Disease -two case studies
Case study 1:
A toddler was hospitalised with fever, cough and grunting. The child was unvaccinated as it was a conscious parental decision. The child was born at 38 weeks and had no previous health issues. A diagnosis of pneumonia was made. The toddler developed a pleural effusion and empyema requiring thoracoscopic surgery and renal failure requiring dialysis. Medical staff are hopeful for the child's long term prognosis; however there are a number of issues requiring continuing health management. The pneumococcal serotype that was responsible for the infection was vaccine preventable. The family have been strongly encouraged to vaccinate their child. This case shows the benefit of appropriate vaccination to reduce the burden of mortality and morbidity amongst a vulnerable age group.
Case study 2:
A toddler with congenital deafness was hospitalised for presumed septic shock. The child was diagnosed with meningitis, their CSF was positive for streptococcus pneumoniae. When serotyping was completed, this case was not a vaccine preventable serotype. However in the two months prior to disease onset, the child had received a cochlea implant, which increases the risk for invasive pneumococcal disease. The child had received three doses of Prevenar 13 ® according to the schedule however was also eligible for an extra Prevenar 13 ® at 12 months of age due to their increased medical risk. Children in this risk category are also recommended to receive a Pneumovax ® 23 vaccine between the age of four and five. It is important for immunisation providers to be alert to any person with a medical risk factor that may increase the risk of invasive pneumococcal disease (IPD) and who require additional pneumococcal vaccine.
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Streptococcus pneumoniae
Streptococcus pneumoniae is one of the most common causes of bacterial meningitis, septicaemia and pneumonia worldwide. The overall incidence rate in Victoria is approximately nine per 100 000 population per year, with a case fatality rate approaching eight per cent, increasing to 20 per cent for pneumococcal meningitis. Septicaemia and meningitis are more common in children, while pneumonia is more frequent in adults. Source: http://ideas.health.vic. gov.au/bluebook/invasive-pneumococcal-disease.asp
The evolution of antibiotic resistant strains of pneumococci is of increasing concern. IPD is defined as the isolation of the organism from a normally sterile site such as blood or cerebrospinal fluid, but not sputum. IPD is a notifiable disease in Victoria. Notifications of IPD show strong seasonality, with a peak in cases notified in late winter. This seasonality may in part be attributable to increased risk of IPD in association with viral respiratory illnesses, particularly influenza. Susceptibility to pneumococcal infection is universal; however the risk of invasive disease is highest for children aged less than two years and adults aged 65 years and over. Other risk factors include prematurity and low birth weight, immune deficiency and immunosuppressive therapy, and exposure to tobacco smoke. 
Immunisation register expansions
As part of the Federal Budget 2015-2016, the Australian Government has approved the expansion of the Australian Childhood Immunisation Register (ACIR) to become the Australian Immunisation Register (AIR). The expanded Register will capture all vaccines given, from birth into adulthood, through GPs and local council immunisation services.
The drivers for this expansion are: a) As part of the Australian Government 'No Jab, No Pay' measure, the ACIR needs to be expanded to capture vaccine records up to the age of 19 years. This is necessary to link family assistance payments to the immunisation status of all children up to this age, not just the very young.
b) As part of the National Shingles Vaccination Program announcement, the Australian Government has agreed that establishment of an adult vaccination register in Australia is important and that ACIR should be expanded to capture all adult vaccines given through GPs and local council immunisation services.
These expansions to ACIR are separate to Minister Ley's Immunisation Budget announcement, which provides funding to expand the existing National HPV Vaccination Program Register (NHVPR) to become the Australian Schools Vaccination Register (ASVR). The ASVR will capture all adolescent vaccinations given through the school programs and will use tools such as recall and reminder systems to improve adolescent vaccination rates.
The timeframes for implementation are:
• 
Australian School Vaccination Register
The first step to improve immunisation rates in adolescents and adults is to understand the current coverage of vaccines given to these groups. At present this is not well understood as there are no comprehensive national data collected for these vaccines, with the exception of Human papillomavirus (HPV). Expanding the existing National HPV Vaccine Register to become an Australian School Vaccination Register (ASVR) will allow capture of all adolescent vaccines given through schoolbased programs. This will provide the tools needed, such as recall and reminder systems, to improve adolescent coverage rates. Adolescent vaccinations delivered in schools will be reported to the expanded register, including vaccinations for diphtheria-tetanus-pertussis, HPV and varicella. The ASVR will be operational in the 2017 school year. Families will be able to access an immunisation history record of all National Immunisation Program vaccinations given to their child in school.
Source: Immunise Australia Program, at <immunise.health.gov.au/internet/immunise/publishing.nsf/Content/current-issues>.
